Literature DB >> 11719505

Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase.

Yan Shen1, Aivar Lookene, Solveig Nilsson, Gunilla Olivecrona.   

Abstract

Apolipoprotein CII (apoCII) activates lipoprotein lipase (LPL). Seven residues, located on one face of a model alpha-helix spanning residues 59-75, are fully conserved in apoCII from ten different animal species. We have mutated these residues one by one. Substitution of Ala(59) by glycine, or Thr(62) and Gly(65) by alanine did not change the activation, indicating that these residues are outside the LPL-binding site. Replacement of Tyr(63), Ile(66), Asp(69), or Gln(70) by alanine lowered the affinity for LPL and the catalytic activity of the LPL-apoCII complex. For each residue several additional replacements were made. Most mutants retained some activating ability, but replacement of Tyr(63) by phenylalanine or tryptophan and Gln(70) by glutamate caused almost complete loss of activity. All mutants bound to liposomes with similar affinity as wild-type apoCII, and they also bound with similar affinity to LPL in the absence of hydrolyzable lipids. However, the inactive mutants did not compete with wild-type apoCII in the activation assay. Therefore, we conclude that the productive apoCII-LPL interaction may be dependent on substrate molecules. In summary, our data demonstrate that residues 63, 66, 69, and 70 are of special importance for the function of apoCII, but no single amino acid residue is absolutely crucial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719505     DOI: 10.1074/jbc.M105421200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

2.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

3.  A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II.

Authors:  Nathan L Meyers; Mikael Larsson; Gunilla Olivecrona; Donald M Small
Journal:  J Biol Chem       Date:  2015-05-29       Impact factor: 5.157

4.  APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men.

Authors:  Gie Ken-Dror; Philippa J Talmud; Steve E Humphries; Fotios Drenos
Journal:  Mol Med       Date:  2010-05-20       Impact factor: 6.354

5.  Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces.

Authors:  Nathan L Meyers; Libo Wang; Olga Gursky; Donald M Small
Journal:  J Lipid Res       Date:  2013-05-13       Impact factor: 5.922

6.  Site-directed mutagenesis of apolipoprotein CII to probe the role of its secondary structure for activation of lipoprotein lipase.

Authors:  Yan Shen; Aivar Lookene; Liyang Zhang; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2009-12-30       Impact factor: 5.157

Review 7.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

8.  Genome-wide reverse genetics framework to identify novel functions of the vertebrate secretome.

Authors:  Michael A Pickart; Eric W Klee; Aubrey L Nielsen; Sridhar Sivasubbu; Eric M Mendenhall; Brent R Bill; Eleanor Chen; Craig E Eckfeldt; Michelle Knowlton; Mara E Robu; Jon D Larson; Yun Deng; Lisa A Schimmenti; Lynda B M Ellis; Catherine M Verfaillie; Matthias Hammerschmidt; Steven A Farber; Stephen C Ekker
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

Review 9.  Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.

Authors:  Chiz-Tzung Chang; Chao-Yuh Yang; Fuu-Jen Tsai; Shih-Yi Lin; Chao-Jung Chen
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

Review 10.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.